Table 2.
Overview of the research on regulating macrophage polarization through PI3K/Akt signaling pathway in the treatment of chronic liver disease.
Disease | Regulation Factor | Research objects | The administration of modeling and dose | Duration | Macrophage polarization | Mechanisms | Reference |
---|---|---|---|---|---|---|---|
Liver fibrosis | ↓PTEN | Mice and cell | CCL4(0.02 mL/g/mouse),; LPS(1000 ng/mL), IL-4 (20 ng/mL) | 8weeks; 24 h | M2↑ | p-Akt↑, p-STAT6↑ | [94] |
Drug-induced liver injury | SMA/CORM2 | Mice and cell | APAP (300 mg/kg) | – | M1↓M2↑ | p-Pi3k↑, p-Akt↑, p-mTOR↑, PCNA↑ | [100] |
Viral hepatitis type B | siRNA/pIL-12@lipo | Cell | – | – | Mø→M1 | p-PI3K↓, p-Akt↓, p-ERK↓, Bcl-2↓, p53↑ | [103] |
HCC | ↓TREM1 | Cell and patients and specimens | – | – | M2→M1 | p-PI3K/PI3K↓, p-Akt/Akt↓, p-mTOR/mTOR↓ | [96] |
GLSP | Mouse and cell | GLSP (800,400,200 μg/mL) | 24 h | Mø→M1 | PI3K↓, p-Akt↓, BAX↑, BCC-2↓, CASD-9↑ | [98] | |
AFP | Cell | LPS(50 ng/mL)+IFN-γ(20 ng/mL); IL-4 (20 ng/mL) +IL-13 (20 ng/mL) | 24 h; 72 h | M1phagocytic ability↓ | PI3K/Akt↑ | [78] |
Abbreviation: PTEN, phosphatase and tensin homolog; CCl4, carbon tetrachloride; LPS, lipopolysaccharide; IL-4, Interleukin-4; KCs, Kupffer cells; SMA/CORM2, styrene maleic acid copolymer (SMA) micelle encapsulating CO releasing molecule; siRNA/pIL-12@lipo, Codelivery of HBx-siRNA and Plasmid Encoding IL-12; HCC, Hepatocellular carcinoma; TREM1, Triggering receptor expressed on myeloid cells 1; THP-1, The human leukemia monocytic cell line; Mø, primary macrophage; GLSP, Ganoderma lucidum Spore Polysaccharide; AFP: alpha-fetoprotein.
The symbols ↑, ↓, and → represent an increase, decrease, and or polarization, respectively.